Aggregated price index
Aggregated price index with volume information
- Pharmaceuticals: Major stocks up 2.2% on average while median return up 1.7% in a day
- Pharmaceuticals: Major stocks up 3.7% on average while median return up 2.6% in a week
- Pharmaceuticals: Major stocks up 17.5% on average while median return up 10.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index is based on equal weighted constituencies returns,Aggregated volume information is based on sum of all constituencies volumes
Related Stocks (click on ticker for detail)
- 1M winners are : Winners for past month are $UROV 97.7%, $GBIO 88.0%, $IMRA 81.9%, $OCUL 79.8%, $CVAC 72.4%
- 1M losers are : Losers for past month are $EDSA -15.0%, $HSTO -21.4%, $BYSI -25.7%, $AYLA -25.7%, $LQDA -29.0%
- 1W winners are : Winners for past week are $IMRA 41.1%, $GBIO 35.0%, $ARCT 28.0%, $OCUL 26.8%, $APRE 26.1%
- 1W losers are : Losers for past week are $ADXN -7.9%, $IMAB -8.8%, $SBPH -9.0%, $LQDA -10.9%, $GRAY -12.2%
Index correlation analysis
Correlation for the past month is 11.1%, for the past 3 months is 12.6%
In the past month for a 5 days rolling window, the highest corrrelation is 22.3%, the lowest correlation is -0.5%, the latest correlation is 10.8%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 73.3% between ALRN and ANVS
The lowest correlation is -51.1% between AKCA and APM
NEW YORK, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from October 15, 2019 through August 7, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Reata Pharmaceuticals, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@paw...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 25, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares, and restricted stock units for an aggregate of 70,200 shares, of its common stock to 11 new employee(s) under Xeris’ Induce...
Expectations of good news on the near horizon are buoying markets right now. Over the past month, both the S&P 500 and the NASDAQ are up 11% to new record highs.Investors are excited at the prospect of a COVID vaccine coming before the winter is out. And the electoral results, that Democrat Joe Biden will ascend to the Presidency while the Republicans will emerge strengthened in Congress, promise the avoidance of extremes typical of divided government. In short, investors are looking forward to ...
Stocks with a COVID-19 vaccine angle have made significant gains on developmental milestones, and in some cases have shown what is arguably irrational exuberance.Irrational Exuberance Or Thought-Out Strategy? The rally seen in vaccine developers has come despite skepticism regarding the safety and efficacy of investigational vaccines being developed with expedited timelines.Normally, it takes about 10-18 years to move a vaccine candidate from discovery to commercialization. In the aftermath of ...
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including: * Evercore ISI 3rd Annual HealthCONx Conference Date: December 1, 2020 Live Presentation Time: 10:55 am ET * Piper San...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
LOS ANGELES, CA / ACCESSWIRE / November 27, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Reata Pharmaceuticals, Inc.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
NEW YORK, NY / ACCESSWIRE / November 26, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc.
AstraZeneca's CEO told Bloomberg that the pharmaceutical company will likely conduct another global trial of the effectiveness of its COVID-19 vaccine trial, following the disclosure that the more effective dosage in the existing Phase 3 clinical trial was actually administered by accident. AstraZeneca and its partner the University of Oxford reported interim results that showed 62% efficacy for a full two-dose regimen, and a 90% efficacy rate for a half-dose followed by a full dose – which th...